China
· Delayed Price · Currency is CNY Shijiazhuang Yiling Pharmaceutical Statistics
Total Valuation
Shijiazhuang Yiling Pharmaceutical has a market cap or net worth of CNY 27.67 billion. The enterprise value is 27.71 billion.
| Market Cap | 27.67B |
| Enterprise Value | 27.71B |
Important Dates
The next estimated earnings date is Monday, October 28, 2024.
| Earnings Date | Oct 28, 2024 |
| Ex-Dividend Date | Jul 19, 2024 |
Share Statistics
Shijiazhuang Yiling Pharmaceutical has 1.67 billion shares outstanding. The number of shares has decreased by -0.00% in one year.
| Shares Outstanding | 1.67B |
| Shares Change (YoY) | -0.00% |
| Shares Change (QoQ) | -0.01% |
| Owned by Insiders (%) | 45.99% |
| Owned by Institutions (%) | 5.55% |
| Float | 375.61M |
Valuation Ratios
The trailing PE ratio is 99.95 and the forward PE ratio is 20.29.
| PE Ratio | 99.95 |
| Forward PE | 20.29 |
| PS Ratio | 3.40 |
| PB Ratio | 2.41 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 30.53, with an EV/FCF ratio of -49.99.
| EV / Earnings | 100.11 |
| EV / Sales | 3.41 |
| EV / EBITDA | 30.53 |
| EV / EBIT | 86.74 |
| EV / FCF | -49.99 |
Financial Position
The company has a current ratio of 1.49, with a Debt / Equity ratio of 0.11.
| Current Ratio | 1.49 |
| Quick Ratio | 0.99 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | 1.41 |
| Debt / FCF | -2.32 |
| Interest Coverage | 7.41 |
Financial Efficiency
Return on equity (ROE) is 2.31% and return on invested capital (ROIC) is 1.55%.
| Return on Equity (ROE) | 2.31% |
| Return on Assets (ROA) | 1.14% |
| Return on Capital (ROIC) | 1.55% |
| Revenue Per Employee | 582,622 |
| Profits Per Employee | 19,832 |
| Employee Count | 13,958 |
| Asset Turnover | 0.46 |
| Inventory Turnover | 1.80 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.05% in the last 52 weeks. The beta is 0.20, so Shijiazhuang Yiling Pharmaceutical's price volatility has been lower than the market average.
| Beta (5Y) | 0.20 |
| 52-Week Price Change | -24.05% |
| 50-Day Moving Average | 15.86 |
| 200-Day Moving Average | 18.82 |
| Relative Strength Index (RSI) | 53.34 |
| Average Volume (20 Days) | 18,036,484 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Shijiazhuang Yiling Pharmaceutical had revenue of CNY 8.13 billion and earned 276.82 million in profits. Earnings per share was 0.17.
| Revenue | 8.13B |
| Gross Profit | 4.15B |
| Operating Income | 319.48M |
| Pretax Income | 394.14M |
| Net Income | 276.82M |
| EBITDA | 898.64M |
| EBIT | 319.48M |
| Earnings Per Share (EPS) | 0.17 |
Balance Sheet
The company has 1.22 billion in cash and 1.28 billion in debt, giving a net cash position of -60.34 million or -0.04 per share.
| Cash & Cash Equivalents | 1.22B |
| Total Debt | 1.28B |
| Net Cash | -60.34M |
| Net Cash Per Share | -0.04 |
| Equity (Book Value) | 11.46B |
| Book Value Per Share | 6.87 |
| Working Capital | 2.16B |
Cash Flow
In the last 12 months, operating cash flow was -260.91 million and capital expenditures -293.39 million, giving a free cash flow of -554.31 million.
| Operating Cash Flow | -260.91M |
| Capital Expenditures | -293.39M |
| Free Cash Flow | -554.31M |
| FCF Per Share | -0.33 |
Margins
Gross margin is 51.02%, with operating and profit margins of 3.93% and 3.40%.
| Gross Margin | 51.02% |
| Operating Margin | 3.93% |
| Pretax Margin | 4.85% |
| Profit Margin | 3.40% |
| EBITDA Margin | 11.05% |
| EBIT Margin | 3.93% |
| FCF Margin | -6.82% |
Dividends & Yields
This stock pays an annual dividend of 0.30, which amounts to a dividend yield of 1.73%.
| Dividend Per Share | 0.30 |
| Dividend Yield | 1.73% |
| Dividend Growth (YoY) | -40.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 314.20% |
| Buyback Yield | 0.00% |
| Shareholder Yield | 1.73% |
| Earnings Yield | 1.00% |
| FCF Yield | -2.00% |
Stock Splits
The last stock split was on July 7, 2021. It was a forward split with a ratio of 1.4.
| Last Split Date | Jul 7, 2021 |
| Split Type | Forward |
| Split Ratio | 1.4 |
Scores
Shijiazhuang Yiling Pharmaceutical has an Altman Z-Score of 5.3.
| Altman Z-Score | 5.3 |
| Piotroski F-Score | n/a |